A 50-year-old woman with migraines and a history of stable coronary artery disease is prescribed Lasmiditan 50 mg for acute treatment. She responds well to the medication during her first attack and asks about its efficacy compared to her previous treatments. In clinical trials, what was the primary efficacy endpoint used to evaluate Lasmiditan’s effectiveness for acute migraine treatment?
